Zealand Pharma A/S (LON: 0NZU)

Market Cap	5.91B
Revenue (ttm)	8.58M
Net Income (ttm)	-117.45M
Shares Out	n/a
EPS (ttm)	-1.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,742
Average Volume	8,590
Open	696.75
Previous Close	711.25
Day's Range	696.00 - 737.00
52-Week Range	38.03 - 107.62
Beta	n/a
RSI	44.77
Earnings Date	Feb 20, 2025

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 253
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NZU

Financial Performance

In 2023, Zealand Pharma's revenue was 342.79 million, an increase of 229.65% compared to the previous year's 103.99 million. Losses were -703.74 million, -41.46% less than in 2022.

Financial numbers in DKK